A Phase I, Open Label, Single Sequence, Drug Interaction Study Evaluating Plasma GSK2248761 and Raltegravir Pharmacokinetics in Healthy Adult Subjects.
Latest Information Update: 29 Aug 2023
At a glance
- Drugs Fosdevirine (Primary) ; Raltegravir (Primary)
- Indications HIV-1 infections
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline; ViiV Healthcare
- 24 Jan 2011 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov record.
- 14 Apr 2010 New trial record